The DTNB Knockout AGS Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated from the AGS human gastric adenocarcinoma epithelial cell line, featuring targeted disruption of the DTNB gene. This polyclonal pool facilitates loss-of-function studies of beta-dystrobrevin in a gastric cancer context, avoiding the selective pressures of clonal derivation and preserving the heterogeneity of editing outcomes.
AGS cells, originally isolated from a gastric adenocarcinoma, are a widely utilized model for gastric cancer research. Their epithelial characteristics and retention of oncogenic signaling pathways make them suitable for investigating genes involved in tumor progression, metastasis, and drug resistance. Employing AGS as the host for DTNB knockout enables direct examination of beta-dystrobrevin function in a tumor-relevant epithelial background.
DTNB encodes beta-dystrobrevin, a cytoplasmic component of the dystrophin-associated glycoprotein complex (DAPC) that links the intracellular actin cytoskeleton to the extracellular matrix via dystroglycan, sarcoglycans, dystrophin, utrophin, and syntrophin. Beta-dystrobrevin interacts directly with dystrophin and syntrophin and is regulated by mechanical stretch, dystrophin, utrophin, and integrin signaling. Downstream, it influences actin organization, nNOS signaling, cell adhesion, and membrane stability, coordinating with focal adhesion components to modulate cytoskeletal dynamics and signal transduction.
In AGS cells, DTNB disruption likely impairs DAPC assembly, affecting cell adhesion, mechanotransduction, and integrin-mediated signaling. This may alter migratory and invasive properties and modulate sensitivity to chemotherapeutic agents. The knockout model thus provides a platform to study how loss of beta-dystrobrevin contributes to gastric adenocarcinoma phenotypes, including potential roles in tumor growth and dissemination.
Key applications include probing DAPC function in gastric cancer cell migration, adhesion, and invasion; evaluating effects on focal adhesion and actin cytoskeleton organization; assessing chemoresistance mechanisms; and modeling gastric cancer progression. Compatible assays encompass western blotting, immunofluorescence, migration/invasion assays, adhesion assays, proliferation and drug sensitivity tests, and transcriptomic profiling. For more details, please contact Ascent Research.
